Article
Radiology, Nuclear Medicine & Medical Imaging
Hugo Levillain, Oreste Bagni, Christophe M. Deroose, Arnaud Dieudonne, Silvano Gnesin, Oliver S. Grosser, S. Cheenu Kappadath, Andrew Kennedy, Nima Kokabi, David M. Liu, David C. Madoff, Armeen Mahvash, Antonio Martinez de la Cuesta, David C. E. Ng, Philipp M. Paprottka, Cinzia Pettinato, Macarena Rodriguez-Fraile, Riad Salem, Bruno Sangro, Lidia Strigari, Daniel Y. Sze, Berlinda J. de Wit van der Veen, Patrick Flamen
Summary: This study established recommendations for the optimisation of selective internal radiation therapy (SIRT) with yttrium-90 (Y-90)-resin microspheres, based on expert panel discussions and survey responses from leading experts in the field. The recommendations cover various aspects of SIRT, including activity prescription, post-treatment dosimetry, and imaging for treatment verification. It is recommended that a multidisciplinary team define treatment strategy and therapeutic intent, and that a personalised approach using dosimetry be adopted for activity prescription. Additionally, post-SIRT imaging and dosimetry are strongly recommended for treatment verification and assessment.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2021)
Review
Biochemistry & Molecular Biology
Carolin Czauderna, Kim Luley, Nikolas von Bubnoff, Jens U. Marquardt
Summary: Liver metastases are the most common site of metastasis in colorectal cancer. Current treatment approaches involve systemic therapies and surgical/interventional strategies, with the use of predictive and prognostic biomarkers leading to improved survival rates. Treatment selection based on patient status, tumor characteristics, and molecular/genetic status is recommended for better outcomes.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Gastroenterology & Hepatology
Wattana Leowattana, Pathomthep Leowattana, Tawithep Leowattana
Summary: Significant progress has been made in the treatment of metastatic colorectal cancer (mCRC) over the past 20 years. Various treatment options are available for first-line treatment of mCRC. Advanced molecular technologies have identified new prognostic and predictive biomarkers for CRC. The development of next-generation sequencing and whole-exome sequencing has greatly advanced DNA sequencing technology and facilitated customized treatment delivery.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Oncology
Eran Nizri, Yaniv Berger, Eraan Green, Matan Kyzer, Asaf Aizic, Nadav Nevo, Fabian Gerstenhaber, Joseph M. Klausner, Mordechai Gutman, Guy Lahat, Aviad Hoffman, Ravit Geva
Summary: This study found that patients with visceral peritoneal colorectal metastases (VPCMs) who also had lymph node metastases (LNMs) may be more prone to systemic recurrence, indicating a potential need for adjuvant treatment.
ANNALS OF SURGICAL ONCOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hai-Ning Chen, Yang Shu, Fei Liao, Xue Liao, Hongying Zhang, Yun Qin, Zhu Wang, Maochao Luo, Qiuluo Liu, Zhinan Xue, Minyuan Cao, Shouyue Zhang, Wei-Han Zhang, Qianqian Hou, Xuyang Xia, Han Luo, Yan Zhang, Lie Yang, Jian-Kun Hu, Xianghui Fu, Bo Liu, Hongbo Hu, Canhua Huang, Yong Peng, Wei Cheng, Lunzhi Dai, Li Yang, Wei Zhang, Biao Dong, Yuan Li, Yuquan Wei, Heng Xu, Zong-Guang Zhou
Summary: The study provides insights into the genomic evolution and metastatic patterns of colorectal cancer, suggesting that biopsy/sequencing of metastases should be considered for patients with multiorgan or late postoperative metastasis.
Article
Surgery
David M. Liu, Thomas W. T. Leung, Pierce K. H. Chow, David C. E. Ng, Rheun-Chuan Lee, Yun Hwan Kim, Yilei Mao, Yu-Fan Cheng, Gao-Jun Teng, Wan Yee Lau
Summary: This study provides guidance and perspectives on the use of selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC) in Asia. Through a systematic literature review and consensus approach, experts developed guidelines and recommendations for the use of SIRT in HCC patients in Asia. The study also highlights the need for further clinical trials to define the role of SIRT in managing HCC among Asian populations.
INTERNATIONAL JOURNAL OF SURGERY
(2022)
Article
Surgery
David M. Liu, Thomas Wt Leung, Pierce Kh Chow, David Ce Ng, Rheun-Chuan Lee, Yun Hwan Kim, Yilei Mao, Yu-Fan Cheng, Gao-Jun Teng, Wan Yee Lau
Summary: This article provides guidelines and perspectives on the use of selective internal radiation therapy (SIRT) with resin yttrium 90 microspheres for hepatocellular carcinoma (HCC) in Asia. The experts developed recommendations using a modified Delphi consensus approach and highlighted the need for further clinical trials to define the role of SIRT in Asian populations with HCC.
INTERNATIONAL JOURNAL OF SURGERY
(2022)
Review
Oncology
Maitham A. Moslim, D. Rohan Jeyarajah
Summary: The management of colorectal liver metastasis is complex and benefits from a multidisciplinary team approach. Selective internal radiation therapy (SIRT) with yttrium-90 (Y-90) can be used as a first-line treatment and to induce future liver remnant hypertrophy for better control of loco-regional disease. There are opportunities to validate the role of SIRT as a first-line therapy in combination with surgical resection.
JOURNAL OF GASTROINTESTINAL ONCOLOGY
(2021)
Review
Medicine, General & Internal
Meritxell Molla, Julen Fernandez-Plana, Santiago Albiol, Constantino Fondevila, Ivan Vollmer, Carla Cases, Angeles Garcia-Criado, Jaume Capdevila, Carles Conill, Yliam Fundora, Carlos Fernandez-Martos, Estela Pineda
Summary: The prognosis for oligometastatic colorectal cancer has improved due to recent advances in new techniques and approaches such as new surgical procedures, better systemic treatments, percutaneous ablation, and stereotactic body radiation therapy. Factors to consider when deciding on the best approach include tumor factors, patient factors, and physician factors. These advances have presented challenges and opportunities for oncologic multidisciplinary teams to treat patients with limited liver and lung metastases.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
C. Stromberg, L. Martinez de la Maza, C. Fernandez Moro, M. Gerling, C. Jorns, E. Sparrelid, M. J. Lohr, C. Villard
Summary: Heterogeneous response to neoadjuvant chemotherapy in patients with colorectal liver metastases is associated with prognosis and can be used as a marker for post-operative therapy decisions.
Review
Oncology
Mohamad Bassam Sonbol, Rabbia Siddiqi, Pedro Luiz Serrano Uson, Surabhi Pathak, Belal Firwana, Gehan Botrus, Diana Almader-Douglas, Daniel H. Ahn, Mitesh J. Borad, Jason Starr, Jeremy Jones, Chee-Chee Stucky, Rory Smoot, Irbaz Bin Riaz, Tanios Bekaii-Saab
Summary: This systematic review and network meta-analysis of 7 randomized controlled trials found that the addition of perioperative systemic treatment can improve disease-free survival in patients with resectable colorectal cancer liver metastasis, but has no significant effect on overall survival. The role of perioperative chemotherapy in colorectal cancer liver metastasis is still unclear.
Article
Oncology
Yuhang Ge, Renshen Xiang, Jun Ren, Wei Song, Wei Lu, Tao Fu
Summary: This study aimed to identify risk factors for multiple metastases in metastatic colorectal cancer patients and develop a functional nomogram for prediction. The nomogram showed good discrimination and calibration in both training and validation groups, indicating its potential clinical utility in predicting multiple metastases.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Guangsheng Zhao, Song Liu, Yuewei Zhang, Tong Zhao, Ruoyu Wang, Jie Bian, Jianlin Wu, Jun Zhou
Summary: DEBIRI-TACE with CSM demonstrates high treatment response, acceptable survival benefits, and good toleration in patients with unresectable CRLM.
IRISH JOURNAL OF MEDICAL SCIENCE
(2022)
Article
Surgery
Ruben A. G. van Eerden, Nadine L. de Boer, Job P. van Kooten, Checca Bakkers, Michelle Dietz, Geert-Jan M. Creemers, Sanne M. Buijs, Ramon Bax, Femke M. de Man, Robin J. Lurvink, Marjolein Diepeveen, Alexandra R. M. Brandt-Kerkhof, Esther van Meerten, Stijn L. W. Koolen, Ignace H. J. T. de Hingh, Cornelis Verhoef, Ron H. J. Mathijssen, Jacobus W. A. Burger, Dutch Peritoneal Oncology Grp, Dutch Colorectal Canc Grp
Summary: The study showed that administration of intraperitoneal irinotecan concomitantly with systemic FOLFOX-bevacizumab every 2 weeks was safe and well tolerated in patients with colorectal peritoneal metastases. The exposure to intraperitoneal SN-38, the active metabolite of irinotecan, was high and prolonged. Therefore, intraperitoneal administration of irinotecan may be a good alternative to other more invasive and costly treatment options.
BRITISH JOURNAL OF SURGERY
(2023)
Article
Behavioral Sciences
Lisa Grech, Bao Sheng Loe, Daphne Day, Daniel Freeman, Alastair Kwok, Mike Nguyen, Nathan Bain, Eva Segelov
Summary: This study developed a scale, DIVAS-6, to assess attitudes and concerns related to COVID-19 vaccination in individuals with underlying diseases. The scale was validated in patients with cancer, diabetes, and multiple sclerosis, showing good psychometric properties and convergent validity. DIVAS-6 can assist in guiding information delivery about COVID-19 vaccination in medically vulnerable populations.
BEHAVIORAL MEDICINE
(2023)
Article
Medicine, General & Internal
Kathleen Batty, Amelia M. Taylor, Elizabeth J. Bernard, Connie Diakos, Stephen J. Clarke, Alexander Guminski, Sally Baron-Hay, Frances Boyle, Nick Pavlakis, David L. Chan
Summary: This study retrospectively analyzed a series of patients with metastatic neuroendocrine carcinoma of the breast to investigate their clinical characteristics, treatment modalities, and prognosis. The results showed that multiple treatment modalities were used with different sequencing in different patients, but the progression-free survival with first-line therapy was short.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Oncology
Yana Debie, Jonas R. M. Van Audenaerde, Timon Vandamme, Lieselot Croes, Laure-Anne Teuwen, Lise Verbruggen, Greetje Vanhoutte, Elly Marcq, Lisa Verheggen, Debbie Le Blon, Bart Peeters, Maria E. Goossens, Pieter Pannus, Kevin K. Arien, Sebastien Anguille, Annelies Janssens, Hans Prenen, Evelien L. J. Smits, Christof Vulsteke, Eva Lion, Marc Peeters, Peter A. van Dam
Summary: Patients with cancer have reduced humoral responses after double-dose COVID-19 vaccination, but their cellular response is comparable to healthy individuals. A third dose of BNT162b2 can boost immune responses in both healthy people and cancer patients. This study compares the effects of a third dose of BNT162b2 after homologous (double-dose BNT162b2) and heterologous (ChAdOx1) vaccination in cancer patients.
CLINICAL CANCER RESEARCH
(2023)
Letter
Oncology
Yana Debie, Peter A. van Dam, Maria E. Goossens, Marc Peeters, Timon Vandamme
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Ian M. Collins, Rob Blum, Eva Segelov, Phillip Parente, Craig Underhill
Summary: This study investigated the current medical oncology workforce in Victoria and found a growing workload and inadequate resources to meet the demand, especially during the global pandemic. The study concludes that there is an urgent need to address the shortage of medical oncology workforce to ensure the quality and efficiency of cancer treatment.
INTERNAL MEDICINE JOURNAL
(2023)
Review
Oncology
Sean Tan, Seiyon Sivakumar, Eva Segelov, Stephen J. Nicholls, J. Nelson
Summary: This study reveals the low reporting frequency of traditional cardiovascular risk factors (CVRF) in immune checkpoint inhibitor (ICI) trials, despite the increased risk of myocardial infarction associated with ICI treatment.
CANCER EPIDEMIOLOGY
(2023)
Article
Oncology
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M. Noonan, Dong-Wan Kim, John H. Strickler, Sang-We Kim, Stephen Clarke, Thomas J. George, Peter S. Grimison, Minal Barve, Manik Amin, Jayesh Desai, Trisha Wise-Draper, Steven Eck, Yu Jiang, Anis A. Khan, Yuling Wu, Philip Martin, Zachary A. Cooper, Nairouz Elgeioushi, Nancy Mueller, Rakesh Kumar, Sandip Pravin Patel
Summary: This study evaluated the use of oleclumab in patients with advanced colorectal cancer, pancreatic ductal adenocarcinoma, and epidermal growth factor receptor-mutant non-small-cell lung cancer. The results showed that oleclumab had a manageable safety profile and demonstrated antitumor activity.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Review
Oncology
Katleen Janssens, Chinouk Lambrechts, Barbara Geerinckx, Ken Op de Beeck, Guy Van Camp, Helena Oliveres, Hans Prenen, Timon Vandamme, Marc Peeters
Summary: One of the major challenges in digestive oncology is selecting the optimal therapy for RAS-mutated metastatic colorectal cancer (mCRC). Recent developments in targeting the RAS-pathway have shown promising results and may lead to clinical benefits for patients in the coming years. Although resistance remains a concern, strategic combination regimens have been developed to overcome this issue. In this review, we summarize the standard of care and discuss emerging therapies for RAS-mutated mCRC.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Article
Oncology
Marc Peeters, Hans-Peter Lipp, Minjeong Park, Ye Chan Yoon, Dirk Arnold
Summary: SB8 is a biosimilar of bevacizumab that has been extensively studied to demonstrate its similarity in various aspects. It is authorized for use in different types of tumors based on the concept of extrapolation. Additionally, SB8 offers the advantage of prolonged stability in diluted form compared to the reference bevacizumab. Although there are concerns about extrapolation, the "totality of evidence" supports the biosimilarity of SB8.
Article
Oncology
Katleen Janssens, Erik Fransen, Guy Van Camp, Hans Prenen, Ken Op de Beeck, Nancy Van Damme, Marc Peeters
Summary: This study provides evidence that left-sided colorectal cancer has a significantly better prognosis compared to right-sided colorectal cancer, in all stages and ages combined. The survival of left-sided colorectal cancer is also longer than right-sided colorectal cancer in stage IV, regardless of MMR, RAS, and BRAF status.
Article
Microbiology
Baptiste Oosterlinck, Hannah Ceuleers, Wout Arras, Joris G. De Man, Karen Geboes, Heiko De Schepper, Marc Peeters, Sarah Lebeer, Jurgita Skieceviciene, Georgina L. Hold, Juozas Kupcinskas, Alexander Link, Benedicte Y. De Winter, Annemieke Smet
Summary: This study identified the mucin-microbiome signatures in gastric adenocarcinomas and their impact on clinical outcomes. The findings showed that intestinal mucin phenotype and high-level MUC13 expression were associated with poor survival, while gastric MUC5AC or MUC6 abundance was associated with a more favorable outcome. Furthermore, oral bacteria such as Neisseria, Prevotella, and Veillonella were found to play a potential role in MUC13 signaling and were associated with intestinal and mixed mucin phenotype tumors.
Article
Oncology
Tamkin Ahmadzada, Abhishek Vijayan, Fatemeh Vafaee, Ali Azimi, Glen Reid, Stephen Clarke, Steven Kao, Georges E. Grau, Elham Hosseini-Beheshti
Summary: In this study, we characterized different populations of extracellular vesicles (EVs) derived from pleural mesothelioma cell lines and identified unique cancer-specific proteomes and oncogenic cargo in each subtype. We also established a comprehensive proteomic database of cancer-associated proteins in EVs, which could serve as new targets for future biomarker studies in pleural mesothelioma.
Article
Chemistry, Medicinal
Danielle Delombaerde, Johan De Sutter, Lieselot Croes, Delphine Vervloet, Veronique Moerman, Nico van de Veire, Anne-Marie Willems, Kristien Wouters, Marc Peeters, Hans Prenen, Christof Vulsteke
Summary: The lack of solid data and prospective studies has resulted in a lack of clear guidelines for cardiovascular monitoring in patients receiving immune checkpoint inhibitors (ICIs). In order to address this issue, we have initiated the CAVACI trial to investigate the short- and long-term cardiovascular effects of ICIs. Patient recruitment started in January 2022.
Article
Oncology
Valerie Desmedt, Aranzazu Jauregui-Amezaga, Liselotte Fierens, Sandrine Aspeslagh, Jeroen Dekervel, Els Wauters, Marc Peeters, Joao Sabino, Lara Crape, Michael Somers, Anne Hoorens, Joris Dutre, Triana Lobaton
Summary: This paper provides updated practice advice on the diagnosis and management of immune checkpoint inhibitor-induced gastrointestinal toxicity for gastroenterologists and oncologists. The use of immune checkpoint inhibitors in cancer immunotherapy has been shown to increase overall survival, but it also carries the risk of severe immune-mediated adverse events, particularly involving the gastrointestinal tract. The paper emphasizes the importance of early multidisciplinary approach and proposes criteria for diagnosis and treatment.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Matthew Anaka, David Chan, Sharon Pattison, Alia Thawer, Bryan Franco, Lesley Moody, Christopher Jackson, Eva Segelov, Simron Singh
Summary: Patients with advanced neuroendocrine tumors have heterogeneous priorities when choosing between treatment options, highlighting the importance of shared decision making for this patient population. Studies suggest that oncologists and patients have different values on treatment attributes, underlining the need for high-quality information to facilitate patient-centered decision making.